Recently, Suzhou Hybiome Biomedical Engineering Co., Ltd. announced the completion of the Pre-IPO round of financing with CNY 100 million. Huatai United Securities acted as the financial advisor in this transaction and introduced investor Zhongrong Trust Dingxin to Hybiome.

After the completion of this financing round, the company will continue to work with investments and agencies to actively promote the IPO process on the SSE STAR Market. As the controlling shareholder BioMérieux is a listed company on the Euronext stock exchange, Suzhou Hybiome is expected to become the first domestic spin-off of a European listed company, realizing the connection between the leading medical enterprise in the European capital market and the Chinese capital market.

Suzhou Hybiome Biomedical Engineering Co. Ltd was co-founded by Suzhou Institute of Biomedical Engineering and Technology, Changchun Institute of Optics and Fine Mechanics and Physics, and Mr. Jianhua Dong in 2009. Suzhou Hybiome is a high-tech enterprise focused on R&D, production, and distribution of in vitro diagnostic products. Its main products include automated chemiluminescence immunoassay (CLIA) analyzers and reagents. They have also been the first Chinese CFDA approved provider of automatic blood grouping analyzers for microcolumn gel card; a blood grouping technology.

At the end of 2018, BioMérieux became the controlling shareholder of the company, and Hybiome began to improve from research and development to production, marketing and sales. At present, the company is accelerating the pace of innovation in various technical platforms, quality control and production processes, enhancing core competitiveness, and developing a broader international market. Now it has built its own flagship product B-R-A-H-M-5 Brahms PCT product. The listing of this product has broken the monopoly of Brahms PCT products by international leading IVD companies, and is currently the only authorized Brahms PCT product in China.